Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status"
- PMID: 35015265
- PMCID: PMC8863724
- DOI: 10.1007/s40263-021-00891-0
Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status"
Conflict of interest statement
Marco Pappagallo, Charles Inturrisi and Paolo Manfredi are paid consultants for Relmada Therapeutics. Charles Inturrisi and Paolo Manfredi are inventors on patents and patent applications related to dextromethadone.
Comment in
-
Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".CNS Drugs. 2022 Feb;36(2):205-206. doi: 10.1007/s40263-021-00892-z. Epub 2022 Jan 11. CNS Drugs. 2022. PMID: 35015266 Free PMC article. No abstract available.
Comment on
-
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.CNS Drugs. 2021 May;35(5):527-543. doi: 10.1007/s40263-021-00816-x. Epub 2021 Apr 26. CNS Drugs. 2021. PMID: 33904154 Free PMC article. Review.
References
-
- Isbell H, Eisenman AJ. The addiction liability of some drugs of the methadone series. J Pharmacol Exp Ther. 1948;93:305–313. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
